Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 5/20 | 0.53 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | NPY4R | P50391 | 1/20 | 0.48 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30865079 | 0.98 | BACE1 (0.58) | BACE1KISS1RBACE2NPY1RNPY2R | |
| SCHEMBL30184172 | 0.97 | KISS1R (0.53) | BACE1KISS1RBACE2OPRM1OPRD1 | |
| SCHEMBL31690550 | 0.97 | KISS1R (0.56) | BACE1KISS1RBACE2VIPR1 | |
| SCHEMBL29678306 | 0.94 | KISS1R (0.56) | BACE1KISS1RBACE2VIPR1 | |
| SCHEMBL31690551 | 0.94 | KISS1R (0.56) | BACE1KISS1RBACE2VIPR1 | |
| SCHEMBL30865069 | 0.94 | KISS1R (0.54) | BACE1KISS1ROPRM1OPRD1OPRK1 | |
| SCHEMBL30712758 | 0.91 | VIPR1 (0.50) | BACE1KISS1RBACE2VIPR1 | |
| SCHEMBL29627568 | 0.90 | KISS1R (0.54) | BACE1KISS1RBACE2VIPR1 | |
| SCHEMBL31696338 | 0.89 | BACE1 (0.67) | BACE1KISS1RBACE2 | |
| SCHEMBL38662087 | 0.88 | BACE1 (0.56) | BACE1KISS1RBACE2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551537-B2 | Methods and compositions for the treatment and prevention of type 1 diabetes | DR. MARY MORRIS & ASSOCIATES, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-20230018324-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF TYPE 1 DIABETES | DR. MARY MORRIS & ASSOCIATES, LLC (US) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551537-B2 | Methods and compositions for the treatment and prevention of type 1 diabetes | IAPP, GLP1R, SLC5A1 | BACE1 498/4885KISS1R 416/4885BACE2 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.